Uniqure NV (NASDAQ:QURE) has been given an average rating of “Buy” by the thirteen research firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $81.86.
A number of research analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating on shares of Uniqure in a research note on Tuesday, September 3rd. Guggenheim downgraded shares of Uniqure from a “buy” rating to a “neutral” rating in a research note on Monday, July 29th. Zacks Investment Research downgraded shares of Uniqure from a “buy” rating to a “hold” rating in a research note on Friday, August 2nd. Chardan Capital reiterated a “buy” rating on shares of Uniqure in a report on Tuesday, September 3rd. Finally, BidaskClub downgraded shares of Uniqure from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 8th.
In other Uniqure news, Director Philip Astley-Sparke sold 6,460 shares of the business’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $60.12, for a total transaction of $388,375.20. Following the completion of the sale, the director now directly owns 12,406 shares in the company, valued at approximately $745,848.72. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Matthew C. Kapusta sold 8,000 shares of the stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $56.48, for a total value of $451,840.00. Following the transaction, the chief executive officer now directly owns 391,230 shares in the company, valued at $22,096,670.40. The disclosure for this sale can be found here. In the last three months, insiders sold 30,460 shares of company stock valued at $2,031,415. 2.91% of the stock is owned by insiders.
Several hedge funds have recently added to or reduced their stakes in the company. Harvest Group Wealth Management LLC bought a new stake in shares of Uniqure in the first quarter worth $26,000. Griffin Asset Management Inc. purchased a new position in Uniqure in the second quarter worth about $39,000. Pearl River Capital LLC purchased a new position in Uniqure in the first quarter worth about $32,000. US Bancorp DE grew its stake in shares of Uniqure by 275.5% during the 2nd quarter. US Bancorp DE now owns 582 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 427 shares during the period. Finally, Rockefeller Capital Management L.P. bought a new stake in shares of Uniqure during the 2nd quarter valued at about $78,000. Hedge funds and other institutional investors own 74.70% of the company’s stock.
QURE traded up $0.13 during midday trading on Friday, reaching $46.95. The company’s stock had a trading volume of 1,485 shares, compared to its average volume of 637,443. Uniqure has a 1 year low of $21.98 and a 1 year high of $82.49. The stock’s 50-day moving average is $56.08 and its 200-day moving average is $62.07. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -20.03 and a beta of 0.96. The company has a current ratio of 8.07, a quick ratio of 8.07 and a debt-to-equity ratio of 0.51.
Uniqure (NASDAQ:QURE) last released its earnings results on Monday, July 29th. The biotechnology company reported ($0.83) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.75) by ($0.08). Uniqure had a negative net margin of 1,232.30% and a negative return on equity of 61.67%. The business had revenue of $2.47 million for the quarter, compared to analysts’ expectations of $1.53 million. As a group, equities research analysts forecast that Uniqure will post -3.2 earnings per share for the current fiscal year.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Featured Article: What are defining characteristics of a correction?
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.